Merck v Pfizer: Here’s how the two new COVID antiviral drugs work and will be used

We have waited 20 months for a drug to blunt the coronavirus, and now two have emerged. Earlier this month, the UK’s drug regulator approved mollupiravir, developed by COVID Antiviral and Ridgeback Therapeutics. In adults with mild to moderate COVID who were at risk for severe illness, it halved the chance of being hospitalized or … Read more